Results 1 to 10 of about 15,373 (177)

Association Between BMI and the Efficacy and Safety of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer: A Multicenter Retrospective Propensity Score Matched Cohort Study (CAMELIA)

MedComm – Oncology, Volume 5, Issue 4, December 2026.
This multicenter real‐world study showed that higher BMI (≥ 25 kg/m2) was independently associated with improved PFS in patients with HR+/HER2− advanced breast cancer receiving CDK4/6 inhibitors. Safety outcomes were comparable between BMI groups, and the findings were consistent across alternative BMI thresholds, suggesting the potential prognostic ...
Min Tian, Yijia Hua, Qian Liu, Nan Jin, Xinyu Wu, Kun Wang, Min Yan, Tao Sun, Chunfang Hao, Yanxia Zhao, Wei Li, Xiang Huang, Yongmei Yin   +12 more
wiley   +1 more source

De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer

International Journal of Cancer, Volume 159, Issue 10, Page 2393-2402, 15 November 2026.
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley   +1 more source

An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.

PLoS ONE, 2017
PurposeTo investigate the effects of trastuzumab (herceptin) and fulvestrant (falsodex) either in combination or alone, on downstream cell signaling pathways in lab-cultured human HR+/HER2+ breast cancer cell lines ZR-75-1 and BT-474, as well as on ...
Qing Chen, Ziyi Weng, Yunshu Lu, Yijun Jia, Longlong Ding, Fang Bai, Meixin Ge, Qing Lin, Kejin Wu   +8 more
doaj   +1 more source

Computational strategies to address therapeutic resistance in estrogen receptor‐positive breast cancer: A narrative review of molecular docking, molecular dynamics simulations, and emerging therapeutic targets

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Computational drug discovery integrates molecular docking, molecular dynamics simulations, and translational clinical targeting to identify next‐generation therapeutics that overcome endocrine resistance in ER‐positive breast cancer. Combined with multi‐omics, artificial intelligence, and biomarker‐guided precision oncology, these approaches accelerate
Emmanuel Ifeanyi Obeagu, Yaregal Asres
wiley   +1 more source

Targeting the PI3K/Akt Signaling Pathway: A Promising Therapeutic Strategy to Reduce Cancer Mortality and Overcome Chemoresistance

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims The phosphatidylinositol 3‐kinase (PI3K)/Akt signaling pathway is a central regulator of cellular properties that are essential for cancer progression, including cellular growth, survival, metabolism, and angiogenesis. Dysregulated PI3K/Akt signaling, often caused by genetic alterations in PIK3CA, loss of PTEN, or the ...
Md Mohiuddin
wiley   +1 more source

Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells

Cellular Physiology and Biochemistry, 2018
Background/Aims: Blocking estrogen signaling with endocrine therapies (Tamoxifen or Fulverstrant) is an effective treatment for Estrogen Receptor-α positive (ER+) breast cancer tumours.
Pratima Basak, Sumanta Chatterjee, Vasudeva Bhat, Alice Su, Hyerang Jin, Victoria Lee-Wing, Qian Liu, Pingzhao Hu, Leigh C Murphy, Afshin Raouf   +9 more
doaj   +1 more source

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR‐Positive, HER2‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Endocrine therapy with CDK4/6 inhibitor has been the main treatment for HR+/HER2− breast cancer in the adjuvant setting; however, the data on the application in the neoadjuvant setting is limited. We compared neoadjuvant efficacy and safety of sequential chemotherapy‐CDK4/6 inhibitors with chemotherapy alone in HR+/HER2− breast ...
Xiaopei Dong, Fan Li, Yang Yuan, Hua Song, Yingzhe Wang, Yi Hao, Yinping Dong, Tao Wang, Li Bian, Shaohua Zhang, Jianbin Li   +10 more
wiley   +1 more source

Imaging Pitfalls in Evaluating Liver Metastases in Breast Cancer With Autosomal Dominant Polycystic Kidney Disease‐Associated Polycystic Liver: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Extensive hepatic cysts in ADPKD, together with a diffuse infiltrative liver metastatic pattern, can lead to radiological underestimation of hepatic tumor burden on conventional whole‐body imaging. Persistent biomarker–imaging discordance should prompt reassessment of disease progression at known sites and involvement of other organs, with ...
Saho Aso, Ritsuko Sasaki, Haruna Kawano, Hiroko Onagi, Harumi Saeki, Misato Okazaki, Kotaro Ijima, Goro Kutomi   +7 more
wiley   +1 more source

4‐Hydroxytamoxifen induces a noncanonical ferroptosis in lung adenocarcinoma by targeting AKR1B10

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
4‑OHT directly inhibits AKR1B10 enzymatic activity to induce noncanonical ferroptosis in LUAD. AKR1B10 sustains LUAD survival by stabilising ACC1 and detoxifying reactive carbonyl species (RCSs). Nanatinostat similarly targets AKR1B10 and elicits the same cell death modality.
Hui Yang, Yanan Wang, Jiangbo Jin, Hanyan Xu, Yinshui Miao, Xiaojing Wu, Shengsong Chen, Tianyu Han, Qingyuan Zhan   +8 more
wiley   +1 more source